Figure S2.

Figure S2. Sephin1 reduces TDP-43 translocation following arsenite treatment.

(A) Representative picture of immunoblots of TDP-43 in nuclear fraction from SH-SY5Y cells treated for 1 h with arsenite 250 μM and recovered for 0, 1, 3, or 6 h in fresh medium containing DMSO or Sephin1 10 μM. (B) Expression level of TDP-43 in nuclear fraction during the recovery period after 1 h of arsenite treatment (n = 3 independent experiments). (C) Expression level of TDP-43 in nuclear fraction during the recovery period after 1 h of arsenite treatment in SH-SY5Y treated with Sephin1 10 μM compared with SH-SY5Y treated with DMSO (n = 3 independent experiments). (D) Representative picture of immunoblot of TDP-43 and STMN2 in RIPA-soluble fraction from SH-SY5Y cells treated for 1 h with arsenite 250 μM and recovered for 0, 1, 3, or 6 h in fresh medium containing DMSO or Sephin1 10 μM. (E) Expression level of TDP-43 in RIPA-soluble fraction during the recovery period after 1 h of arsenite treatment (n = 3 independent experiments). (F) Expression level of TDP-43 in RIPA-soluble fraction during the recovery period after 1 h of arsenite treatment in SH-SY5Y treated with Sephin1 10 μM compared with SH-SY5Y treated with DMSO (n = 3 independent experiments). (G) Representative picture of immunoblot of TDP-43 in RIPA-insoluble fraction from SH-SY5Y cells treated for 1 h with arsenite 250 μM and recovered for 0, 1, 3, or 6 h in fresh medium containing DMSO or Sephin1 10 μM. (H) Expression level of TDP-43 in RIPA-insoluble fraction during the recovery period after 1 h of arsenite treatment (n = 3 independent experiments). (I) Expression level of TDP-43 in RIPA-insoluble fraction during the recovery period after 1 h of arsenite treatment in SH-SY5Y treated with Sephin1 10 μM compared with SH-SY5Y treated with DMSO (n = 3 independent experiments). (J) Expression level of STMN2 in RIPA-soluble fraction during the recovery period after 1 h of arsenite treatment (n = 3 independent experiments). (K) Expression level of STMN2 in RIPA-soluble fraction during the recovery period after 1 h of arsenite treatment in SH-SY5Y treated with Sephin1 10 μM compared with SH-SY5Y treated with DMSO (n = 3 independent experiments). *P < 0.05 Friedman test followed by Dunn’s multiple comparison test; ^&P < 0.05 two-Way ANOVA followed by Tukey’s multiple comparison test. Mean ± SEM.

Source data are available for this figure.